Protecting the poor metaboliser--from what?
出版信息
Br J Clin Pharmacol. 1984 Apr;17(4):488-96. doi: 10.1111/j.1365-2125.1984.tb02380.x.
Abstract
摘要
相似文献
1
Protecting the poor metaboliser--from what?保护代谢缓慢者——免受什么影响？
Br J Clin Pharmacol. 1984 Apr;17(4):488-96. doi: 10.1111/j.1365-2125.1984.tb02380.x.
2
Pharmacogenetic polymorphism of drug metabolism.
N Z Med J. 1984 Aug 22;97(762):567-9.
3
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
4
Prevalence of drug hydroxylator phenotypes in Belgium.比利时药物羟化酶表型的流行情况。
Eur J Clin Pharmacol. 1987;33(4):439-40. doi: 10.1007/BF00637647.
5
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中，美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
6
Metabolic basis of adverse drug reactions.药物不良反应的代谢基础
J R Coll Physicians Lond. 1986 Jul;20(3):195-200.
7
Genetic polymorphism of drug metabolism in humans.
Adv Exp Med Biol. 1991;283:627-40. doi: 10.1007/978-1-4684-5877-0_79.
8
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
9
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.美托洛尔在异喹胍代谢快者和慢者中的差异立体选择性代谢。
Clin Pharmacol Ther. 1983 Dec;34(6):732-7. doi: 10.1038/clpt.1983.242.
10
Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping.美托洛尔所致肝炎：再次激发试验与药物氧化表型分析
Ann Intern Med. 1988 Jan;108(1):67-8. doi: 10.7326/0003-4819-108-1-67.
引用本文的文献
1
Genetically determined adverse drug reactions involving metabolism.涉及代谢的基因决定的药物不良反应。
Drug Saf. 1993 Jul;9(1):60-77. doi: 10.2165/00002018-199309010-00006.
2
Variability of plasma drug concentrations--a reply.血浆药物浓度的变异性——答复
Eur J Clin Pharmacol. 1984;26(5):659. doi: 10.1007/BF00543508.
3
Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.在健康受试者中，异喹胍氧化表型对美托洛尔和阿替洛尔治疗后的运动耐量和主观疲劳的影响。
Br J Clin Pharmacol. 1991 Apr;31(4):391-8. doi: 10.1111/j.1365-2125.1991.tb05551.x.
本文引用的文献
1
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
2
Lack of evidence for polymorphism in metoprolol metabolism.美托洛尔代谢中缺乏多态性的证据。
Br J Clin Pharmacol. 1983 Aug;16(2):188-90. doi: 10.1111/j.1365-2125.1983.tb04984.x.
3
Treatment of angina pectoris with nifedipine.硝苯地平治疗心绞痛
Br Med J (Clin Res Ed). 1983 Jun 18;286(6382):1978-9. doi: 10.1136/bmj.286.6382.1978-e.
4
Protecting poor metabolizers, a group at high risk of adverse drug reactions.
Lancet. 1983 Jun 18;1(8338):1388. doi: 10.1016/s0140-6736(83)92172-4.
5
Polymorphism of carbon oxidation of drugs and clinical implications.药物碳氧化的多态性及其临床意义。
Br Med J. 1978 Sep 2;2(6138):655-7. doi: 10.1136/bmj.2.6138.655.
Zotero 插件